The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Radiotherapy bridging for axi-cel in large B-cell lymphoma
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the use of CAR-T therapy for large B-cell lymphoma. Dr Nastoupil focuses on bridging interventions prior to CAR-T therapy, since many patients have highly symptomatic, rapidly progressive disease that if left untreated during the 3-4 week manufacturing interval could be fatal. Preliminary data suggests that radiotherapy can be an effective bridging tool for relapsed/refractory (R/R) large B-cell lymphoma before axicabtagene ciloleucel (axi-cel) therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
